Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 7/20 | 0.49 |
| ▸ | PANK3 | Q9H999 | 6/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | SORD | Q00796 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19012728 | 1.00 | ACACB (0.49) | ACACBPANK3HSD11B1ENPP2SORD | |
| SCHEMBL19012474 | 0.89 | ACACB (0.48) | ACACBPANK3HSD11B1ENPP2 | |
| SCHEMBL19012704 | 0.89 | ACACB (0.48) | ACACBPANK3HSD11B1ENPP2 | |
| SCHEMBL19012599 | 0.86 | HRH3 (0.43) | ACACBPANK3HSD11B1SORD | |
| SCHEMBL18436271 | 0.86 | HRH3 (0.43) | ACACBPANK3HSD11B1SORD | |
| SCHEMBL19012473 | 0.84 | ACACB (0.48) | ACACBPANK3HSD11B1ENPP2 | |
| SCHEMBL20034196 | 0.84 | ACACB (0.48) | ACACBPANK3HSD11B1ENPP2 | |
| SCHEMBL20034306 | 0.84 | ACACB (0.48) | ACACBPANK3HSD11B1ENPP2 | |
| SCHEMBL19012539 | 0.84 | ACACB (0.54) | ACACBPANK3HSD11B1 | |
| SCHEMBL19012726 | 0.84 | ACACB (0.48) | ACACBPANK3HSD11B1ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938292-B2 | Quinoline derivatives as SMO inhibitors | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-04-10 | — | — | US | disclosed |
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | SMO, GLI1, SHH | ACACB 3908/4885PANK3 2245/4885HSD11B1 3620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.